ArticleLaryngoscope investigative otolaryngology2026
Osteoradionecrosis After Modern Radiotherapy for Oral Cavity Cancer: Incidence and Risk Factors.
Article in Laryngoscope investigative otolaryngology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Personalized Prevention of Osteoradionecrosis of the Jaws: From Clinical Risk Profiling and Site-Specific Dosimetry to Artificial Intelligence and Individualized Treatment-Effect Estimation.Journal of personalized medicine · 2026Review
- Osteoradionecrosis After Modern Radiotherapy for Oral Cavity Cancer: Incidence and Risk Factors.Laryngoscope investigative otolaryngology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Osteoradionecrosis (ORN) incidence after head and neck cancer (HNC) directed radiation therapy has recently been reported to be 1%-40%. The objective of this study is to establish contemporary incidence of ORN for patients treated with IMRT exclusively for oral cavity squamous cell carcinoma (OCSCC). Methods: This study is a retrospective chart review of 172 patients treated for OCSCC at a single institution from 2013 to 2022. All patients received adjuvant radiation with or without chemotherapy. Patient charts were reviewed to identify ORN. ORN was defined as exposure of bone with radiographic findings and/or physical exam findings. Data collected including age, gender, smoking status, AJCC 8th edition stage, mandibulectomy or maxillectomy as part of surgery, hospitalization in between surgery and RT, and concurrent chemotherapy. Results: Mean follow up for the entire cohort was 46.1 months. The incidence of ORN in our cohort of patients was 24% at 3 years. 51.5% of patients underwent mandibulectomy or maxillectomy prior to radiation. 28.4% of patients with mandibulectomy or maxillectomy developed ORN. 18.1% of the patients treated without mandibulectomy or maxillectomy went on to develop ORN. Hazard ratio for development of ORN when patients underwent mandibulectomy or maxillectomy was 1.93. Conclusion: ORN development is higher in oral cavity SCC when compared to published ORN rates in mixed HNC cohorts. Mandibulectomy and/or maxillectomy as part of surgical treatment for OCSCC increases risk for ORN development. Level of Evidence: Level 3.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.